Topical Vancomycin Paste Over the Sternal Edge During Cardiac Surgery: Effects of Renal Function and Body Size on Systemic Exposure
•Body size and renal status affect plasma exposure after topical sternal vancomycin.•Minimal systemic exposure, even with small body size or impaired renal function.•For hemodialysis patients, accumulation of plasma vancomycin is worth cautioning. Intraoperative topical vancomycin has been widely us...
Saved in:
Published in | Clinical therapeutics Vol. 47; no. 2; pp. 135 - 142 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.02.2025
Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | •Body size and renal status affect plasma exposure after topical sternal vancomycin.•Minimal systemic exposure, even with small body size or impaired renal function.•For hemodialysis patients, accumulation of plasma vancomycin is worth cautioning.
Intraoperative topical vancomycin has been widely used in several surgical fields to prevent wound infection. However, there have been limited studies on the systemic exposure of topical vancomycin. The aim of this study was to investigate systemic exposure after topical vancomycin over the sternal edge in cardiac surgical patients. The impact of impaired renal function and body size on the exposure was also examined.
Topical vancomycin (2.5 g) was applied to the sternal edge in 129 adult cardiac surgical patients. Plasma concentrations were measured on postoperative days 0 through 7 and analyzed using linear mixed-effects models.
Sixty (46.5%) patients were in chronic kidney disease stages 3 to 5, including 20 patients in end-stage renal disease (ERSD) status with regular hemodialysis preoperatively. A total of 377 plasma vancomycin levels were modeled. It was reported that there was a 7.7% increase in vancomycin level per postoperative day for patients with ESRD in contrast to a decrease of 6.1% each day for patients without ESRD. Every increase of 1 mL/min/1.73 m2 in the estimated glomerular filtration rate is associated with a 0.9% decline in vancomycin concentration. Increasing body surface area (BSA) by 0.1 m2 reduces the vancomycin level by 6.3%. Model simulations using 10,000 replicates reported that the probability of vancomycin level >10 mg/L declines to near 0 within 1 week after surgery in patients without ESRD, even in subjects with low estimated glomerular filtration rate and BSA. For the ESRD group with a BSA <2 m2, the chance of vancomycin >10 mg/L is up to 20% to 30%.
Plasma exposure after topical vancomycin for the sternal edge is influenced by renal function and body size. The low probability of significant plasma vancomycin levels supports the typical fixed-dose strategy. For patients with ESRD receiving hemodialysis, accumulation of plasma vancomycin is worth cautioning.
[Display omitted] |
---|---|
AbstractList | Intraoperative topical vancomycin has been widely used in several surgical fields to prevent wound infection. However, there have been limited studies on the systemic exposure of topical vancomycin. The aim of this study was to investigate systemic exposure after topical vancomycin over the sternal edge in cardiac surgical patients. The impact of impaired renal function and body size on the exposure was also examined.PURPOSEIntraoperative topical vancomycin has been widely used in several surgical fields to prevent wound infection. However, there have been limited studies on the systemic exposure of topical vancomycin. The aim of this study was to investigate systemic exposure after topical vancomycin over the sternal edge in cardiac surgical patients. The impact of impaired renal function and body size on the exposure was also examined.Topical vancomycin (2.5 g) was applied to the sternal edge in 129 adult cardiac surgical patients. Plasma concentrations were measured on postoperative days 0 through 7 and analyzed using linear mixed-effects models.METHODSTopical vancomycin (2.5 g) was applied to the sternal edge in 129 adult cardiac surgical patients. Plasma concentrations were measured on postoperative days 0 through 7 and analyzed using linear mixed-effects models.Sixty (46.5%) patients were in chronic kidney disease stages 3 to 5, including 20 patients in end-stage renal disease (ERSD) status with regular hemodialysis preoperatively. A total of 377 plasma vancomycin levels were modeled. It was reported that there was a 7.7% increase in vancomycin level per postoperative day for patients with ESRD in contrast to a decrease of 6.1% each day for patients without ESRD. Every increase of 1 mL/min/1.73 m2 in the estimated glomerular filtration rate is associated with a 0.9% decline in vancomycin concentration. Increasing body surface area (BSA) by 0.1 m2 reduces the vancomycin level by 6.3%. Model simulations using 10,000 replicates reported that the probability of vancomycin level >10 mg/L declines to near 0 within 1 week after surgery in patients without ESRD, even in subjects with low estimated glomerular filtration rate and BSA. For the ESRD group with a BSA <2 m2, the chance of vancomycin >10 mg/L is up to 20% to 30%.FINDINGSSixty (46.5%) patients were in chronic kidney disease stages 3 to 5, including 20 patients in end-stage renal disease (ERSD) status with regular hemodialysis preoperatively. A total of 377 plasma vancomycin levels were modeled. It was reported that there was a 7.7% increase in vancomycin level per postoperative day for patients with ESRD in contrast to a decrease of 6.1% each day for patients without ESRD. Every increase of 1 mL/min/1.73 m2 in the estimated glomerular filtration rate is associated with a 0.9% decline in vancomycin concentration. Increasing body surface area (BSA) by 0.1 m2 reduces the vancomycin level by 6.3%. Model simulations using 10,000 replicates reported that the probability of vancomycin level >10 mg/L declines to near 0 within 1 week after surgery in patients without ESRD, even in subjects with low estimated glomerular filtration rate and BSA. For the ESRD group with a BSA <2 m2, the chance of vancomycin >10 mg/L is up to 20% to 30%.Plasma exposure after topical vancomycin for the sternal edge is influenced by renal function and body size. The low probability of significant plasma vancomycin levels supports the typical fixed-dose strategy. For patients with ESRD receiving hemodialysis, accumulation of plasma vancomycin is worth cautioning.IMPLICATIONSPlasma exposure after topical vancomycin for the sternal edge is influenced by renal function and body size. The low probability of significant plasma vancomycin levels supports the typical fixed-dose strategy. For patients with ESRD receiving hemodialysis, accumulation of plasma vancomycin is worth cautioning. Intraoperative topical vancomycin has been widely used in several surgical fields to prevent wound infection. However, there have been limited studies on the systemic exposure of topical vancomycin. The aim of this study was to investigate systemic exposure after topical vancomycin over the sternal edge in cardiac surgical patients. The impact of impaired renal function and body size on the exposure was also examined. Topical vancomycin (2.5 g) was applied to the sternal edge in 129 adult cardiac surgical patients. Plasma concentrations were measured on postoperative days 0 through 7 and analyzed using linear mixed-effects models. Sixty (46.5%) patients were in chronic kidney disease stages 3 to 5, including 20 patients in end-stage renal disease (ERSD) status with regular hemodialysis preoperatively. A total of 377 plasma vancomycin levels were modeled. It was reported that there was a 7.7% increase in vancomycin level per postoperative day for patients with ESRD in contrast to a decrease of 6.1% each day for patients without ESRD. Every increase of 1 mL/min/1.73 m in the estimated glomerular filtration rate is associated with a 0.9% decline in vancomycin concentration. Increasing body surface area (BSA) by 0.1 m reduces the vancomycin level by 6.3%. Model simulations using 10,000 replicates reported that the probability of vancomycin level >10 mg/L declines to near 0 within 1 week after surgery in patients without ESRD, even in subjects with low estimated glomerular filtration rate and BSA. For the ESRD group with a BSA <2 m , the chance of vancomycin >10 mg/L is up to 20% to 30%. Plasma exposure after topical vancomycin for the sternal edge is influenced by renal function and body size. The low probability of significant plasma vancomycin levels supports the typical fixed-dose strategy. For patients with ESRD receiving hemodialysis, accumulation of plasma vancomycin is worth cautioning. Highlights•Body size and renal status affect plasma exposure after topical sternal vancomycin. •Minimal systemic exposure, even with small body size or impaired renal function. •For hemodialysis patients, accumulation of plasma vancomycin is worth cautioning. •Body size and renal status affect plasma exposure after topical sternal vancomycin.•Minimal systemic exposure, even with small body size or impaired renal function.•For hemodialysis patients, accumulation of plasma vancomycin is worth cautioning. Intraoperative topical vancomycin has been widely used in several surgical fields to prevent wound infection. However, there have been limited studies on the systemic exposure of topical vancomycin. The aim of this study was to investigate systemic exposure after topical vancomycin over the sternal edge in cardiac surgical patients. The impact of impaired renal function and body size on the exposure was also examined. Topical vancomycin (2.5 g) was applied to the sternal edge in 129 adult cardiac surgical patients. Plasma concentrations were measured on postoperative days 0 through 7 and analyzed using linear mixed-effects models. Sixty (46.5%) patients were in chronic kidney disease stages 3 to 5, including 20 patients in end-stage renal disease (ERSD) status with regular hemodialysis preoperatively. A total of 377 plasma vancomycin levels were modeled. It was reported that there was a 7.7% increase in vancomycin level per postoperative day for patients with ESRD in contrast to a decrease of 6.1% each day for patients without ESRD. Every increase of 1 mL/min/1.73 m2 in the estimated glomerular filtration rate is associated with a 0.9% decline in vancomycin concentration. Increasing body surface area (BSA) by 0.1 m2 reduces the vancomycin level by 6.3%. Model simulations using 10,000 replicates reported that the probability of vancomycin level >10 mg/L declines to near 0 within 1 week after surgery in patients without ESRD, even in subjects with low estimated glomerular filtration rate and BSA. For the ESRD group with a BSA <2 m2, the chance of vancomycin >10 mg/L is up to 20% to 30%. Plasma exposure after topical vancomycin for the sternal edge is influenced by renal function and body size. The low probability of significant plasma vancomycin levels supports the typical fixed-dose strategy. For patients with ESRD receiving hemodialysis, accumulation of plasma vancomycin is worth cautioning. [Display omitted] Purpose Intraoperative topical vancomycin has been widely used in several surgical fields to prevent wound infection. However, there have been limited studies on the systemic exposure of topical vancomycin. The aim of this study was to investigate systemic exposure after topical vancomycin over the sternal edge in cardiac surgical patients. The impact of impaired renal function and body size on the exposure was also examined. Methods Topical vancomycin (2.5 g) was applied to the sternal edge in 129 adult cardiac surgical patients. Plasma concentrations were measured on postoperative days 0 through 7 and analyzed using linear mixed-effects models. Findings Sixty (46.5%) patients were in chronic kidney disease stages 3 to 5, including 20 patients in end-stage renal disease (ERSD) status with regular hemodialysis preoperatively. A total of 377 plasma vancomycin levels were modeled. It was reported that there was a 7.7% increase in vancomycin level per postoperative day for patients with ESRD in contrast to a decrease of 6.1% each day for patients without ESRD. Every increase of 1 mL/min/1.73 m 2 in the estimated glomerular filtration rate is associated with a 0.9% decline in vancomycin concentration. Increasing body surface area (BSA) by 0.1 m 2 reduces the vancomycin level by 6.3%. Model simulations using 10,000 replicates reported that the probability of vancomycin level >10 mg/L declines to near 0 within 1 week after surgery in patients without ESRD, even in subjects with low estimated glomerular filtration rate and BSA. For the ESRD group with a BSA <2 m 2, the chance of vancomycin >10 mg/L is up to 20% to 30%. Implications Plasma exposure after topical vancomycin for the sternal edge is influenced by renal function and body size. The low probability of significant plasma vancomycin levels supports the typical fixed-dose strategy. For patients with ESRD receiving hemodialysis, accumulation of plasma vancomycin is worth cautioning. |
Author | Luo, Chwan-Yau Wang, Yi-Chen Hu, Yu-Ning Roan, Jun-Neng Kan, Chung-Dann Chou, Chen-Hsi Tsai, Meng-Ta |
Author_xml | – sequence: 1 givenname: Meng-Ta surname: Tsai fullname: Tsai, Meng-Ta organization: Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan – sequence: 2 givenname: Yu-Ning surname: Hu fullname: Hu, Yu-Ning organization: Division of Cardiovascular Surgery, Department of Surgery, National Cheng Kung University Hospital and College of Medicine, Tainan, Taiwan – sequence: 3 givenname: Jun-Neng surname: Roan fullname: Roan, Jun-Neng organization: Division of Cardiovascular Surgery, Department of Surgery, National Cheng Kung University Hospital and College of Medicine, Tainan, Taiwan – sequence: 4 givenname: Chung-Dann surname: Kan fullname: Kan, Chung-Dann organization: Division of Cardiovascular Surgery, Department of Surgery, National Cheng Kung University Hospital and College of Medicine, Tainan, Taiwan – sequence: 5 givenname: Yi-Chen surname: Wang fullname: Wang, Yi-Chen organization: Division of Cardiovascular Surgery, Department of Surgery, E-Da Hospital/I-Shou University, Kaohsiung, Taiwan – sequence: 6 givenname: Chwan-Yau surname: Luo fullname: Luo, Chwan-Yau organization: Division of Cardiovascular Surgery, Department of Surgery, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan – sequence: 7 givenname: Chen-Hsi orcidid: 0000-0003-0708-3657 surname: Chou fullname: Chou, Chen-Hsi email: chenhsi@mail.ncku.edu.tw organization: Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39706762$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkkFvEzEQhS1URNPCXwBLXLhk8djr3SwHUAkpIFUqIgVxs1x7NjgkdrB3K5YrfxyvUnKohNTTSNY3zzPvzQk58sEjIc-AFcCgerkuzMb57jtGXXDGywKgyOUBmcCsbqYA5bcjMmFQNlPewOyYnKS0ZoyJRvJH5Fg0Navqik_In6uwc0Zv6FftTdgOxnn6SacO6eUNRpp_oMsOo8_Ewq6Qvuuj8ys619E6beiyjyuMwyu6aFs0XaKhpZ9xpM97bzoXPNXe0rfBDnTpfiPND8shy2-doYtfu5D6iI_Jw1ZvEj65rafky_niav5henH5_uP87GJqSll1U2wRZ9C02sjrRguLUEkjRSu1nPGytdZg2zSGAzLNa2khQ1yLqmLImKxLcUpe7HV3MfzsMXVq65LBzUZ7DH1SAsq6qQWXs4w-v4OuQz-6MFKVKAVIAZl6ekv111u0ahfdVsdB_bM3A_UeMDGkFLE9IMDUGKRaq0OQagxSAahccufZvhOzITcOo0rGoTdoXcxGKxvcPTRe39EYuTHtHzhgOmwEKnHF1HI8l_FaeJkPpebj-G_-L3CvEf4CwTLU6w |
Cites_doi | 10.1016/j.jtcvs.2016.01.060 10.1086/663708 10.1016/j.jtcvs.2014.06.045 10.1016/j.athoracsur.2016.10.020 10.1016/j.jtcvs.2019.11.004 10.1097/BRS.0000000000000465 10.1111/iwj.14074 10.1016/j.jtcvs.2019.11.137 10.1097/BRS.0b013e3181ff2cb1 10.1016/S0022-5223(19)34366-1 10.1016/j.athoracsur.2021.11.012 10.1002/jssc.201500600 10.1111/j.1540-8191.2011.01300.x 10.1016/j.arth.2015.10.015 10.1016/j.surg.2023.05.031 10.1016/S1010-7940(03)00033-2 10.1111/j.1469-0691.2006.01344.x 10.1016/j.athoracsur.2021.09.036 |
ContentType | Journal Article |
Copyright | 2024 Elsevier Inc. Elsevier Inc. Copyright © 2024 Elsevier Inc. All rights reserved. 2024. Elsevier Inc. |
Copyright_xml | – notice: 2024 Elsevier Inc. – notice: Elsevier Inc. – notice: Copyright © 2024 Elsevier Inc. All rights reserved. – notice: 2024. Elsevier Inc. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88C 88E 8AO 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH K9. KB0 M0S M0T M1P M2O M7N MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI Q9U 7X8 |
DOI | 10.1016/j.clinthera.2024.11.024 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Research Library (ProQuest) Algology Mycology and Protozoology Abstracts (Microbiology C) Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE Research Library Prep |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1879-114X |
EndPage | 142 |
ExternalDocumentID | 39706762 10_1016_j_clinthera_2024_11_024 S0149291824003722 1_s2_0_S0149291824003722 |
Genre | Journal Article |
GeographicLocations | Japan |
GeographicLocations_xml | – name: Japan |
GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 123 1B1 1P~ 1~. 1~5 29B 4.4 457 4G. 53G 5RE 5VS 6J9 6PF 7-5 71M 7RV 7X7 88E 8AO 8FI 8FJ 8G5 8P~ AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABUWG ABWVN ABXDB ABZDS ACDAQ ACIEU ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALCLG ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AQUVI ASPBG AVWKF AXJTR AZFZN AZQEC BENPR BKEYQ BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EBS EFJIC EFKBS EJD EMOBN EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HMCUK HVGLF HZ~ H~9 IHE J1W KOM M0T M1P M2O M41 MO0 N9A NAPCQ O-L O9- OAUVE OD~ OGGZJ OO0 OZT P-8 P-9 PC. PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO Q38 R2- ROL RPZ SCC SDF SDG SEL SES SEW SPCBC SSH SSP SSZ SV3 T5K UHS UKHRP WH7 WOW XOL Z5R ZGI ZXP ~G- 0SF 3V. AACTN AAYOK AFCTW AFKWA AJOXV ALIPV AMFUW NCXOZ RIG AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7XB 8FK K9. M7N MBDVC PKEHL PQEST PQUKI Q9U 7X8 |
ID | FETCH-LOGICAL-c456t-efee819fac5b9a3de165c53f5a5824fddcef99c21e0a275d19a32a3660e005743 |
IEDL.DBID | 7X7 |
ISSN | 0149-2918 1879-114X |
IngestDate | Mon Jul 21 11:37:59 EDT 2025 Wed Aug 13 09:10:21 EDT 2025 Mon Jul 21 05:47:28 EDT 2025 Tue Jul 01 04:22:00 EDT 2025 Sat Feb 15 15:52:17 EST 2025 Mon Feb 24 20:12:03 EST 2025 Tue Aug 26 16:32:08 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Systemic exposure Renal function Body surface area Cardiac surgery Sternum Topical vancomycin |
Language | English |
License | Copyright © 2024 Elsevier Inc. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c456t-efee819fac5b9a3de165c53f5a5824fddcef99c21e0a275d19a32a3660e005743 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0003-0708-3657 |
PMID | 39706762 |
PQID | 3163431531 |
PQPubID | 1226358 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_3147973258 proquest_journals_3163431531 pubmed_primary_39706762 crossref_primary_10_1016_j_clinthera_2024_11_024 elsevier_sciencedirect_doi_10_1016_j_clinthera_2024_11_024 elsevier_clinicalkeyesjournals_1_s2_0_S0149291824003722 elsevier_clinicalkey_doi_10_1016_j_clinthera_2024_11_024 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2025-02-01 |
PublicationDateYYYYMMDD | 2025-02-01 |
PublicationDate_xml | – month: 02 year: 2025 text: 2025-02-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Bridgewater |
PublicationTitle | Clinical therapeutics |
PublicationTitleAlternate | Clin Ther |
PublicationYear | 2025 |
Publisher | Elsevier Inc Elsevier Limited |
Publisher_xml | – name: Elsevier Inc – name: Elsevier Limited |
References | Pervaiz, Chaudhry, Javaid (bib0010) 2019; 5 Khan, Din, Ehsanullah (bib0007) 2019; 30 Johnson, Nessler, Horazdovsky (bib0001) 2017; 32 Servito, Khani-Hanjani, Smith (bib0011) 2022; 114 Lander, Ejiofor, McGurk (bib0016) 2017; 103 Vander Salm, Okike (bib0017) 1989; 98 Lazar, Barlam, Cabral (bib0008) 2011; 26 Mascitti, Edelstein, Fishman (bib0019) 2012; 33 Sweet, Roh, Sliva (bib0018) 2011; 36 Desmond, Lovering, Harle (bib0005) 2003; 23 Javorska, Krcmova, Solichova (bib0013) 2016; 39 Lazar, Salm, Engelman (bib0003) 2016; 152 Donovan, Sino, Paraforos (bib0006) 2022; 114 Kowalewski, Pasierski, Makhoul (bib0002) 2023; 174 Griffin, Teixeira, Ambruso (bib0014) 2021; 161 Zhang, Zhang, Li (bib0012) 2023; 20 Priyanka, Zarbock, Izawa (bib0015) 2021; 162 Armaghani, Menge, Lovejoy (bib0004) 2014; 39 Appelbaum (bib0020) 2006; 12 Lazar, Ketchedjian, Haime (bib0009) 2014; 148 Lazar (10.1016/j.clinthera.2024.11.024_bib0008) 2011; 26 Javorska (10.1016/j.clinthera.2024.11.024_bib0013) 2016; 39 Vander Salm (10.1016/j.clinthera.2024.11.024_bib0017) 1989; 98 Lander (10.1016/j.clinthera.2024.11.024_bib0016) 2017; 103 Desmond (10.1016/j.clinthera.2024.11.024_bib0005) 2003; 23 Mascitti (10.1016/j.clinthera.2024.11.024_bib0019) 2012; 33 Priyanka (10.1016/j.clinthera.2024.11.024_bib0015) 2021; 162 Appelbaum (10.1016/j.clinthera.2024.11.024_bib0020) 2006; 12 Pervaiz (10.1016/j.clinthera.2024.11.024_bib0010) 2019; 5 Zhang (10.1016/j.clinthera.2024.11.024_bib0012) 2023; 20 Servito (10.1016/j.clinthera.2024.11.024_bib0011) 2022; 114 Johnson (10.1016/j.clinthera.2024.11.024_bib0001) 2017; 32 Lazar (10.1016/j.clinthera.2024.11.024_bib0009) 2014; 148 Donovan (10.1016/j.clinthera.2024.11.024_bib0006) 2022; 114 Lazar (10.1016/j.clinthera.2024.11.024_bib0003) 2016; 152 Armaghani (10.1016/j.clinthera.2024.11.024_bib0004) 2014; 39 Griffin (10.1016/j.clinthera.2024.11.024_bib0014) 2021; 161 Sweet (10.1016/j.clinthera.2024.11.024_bib0018) 2011; 36 Kowalewski (10.1016/j.clinthera.2024.11.024_bib0002) 2023; 174 Khan (10.1016/j.clinthera.2024.11.024_bib0007) 2019; 30 |
References_xml | – volume: 36 start-page: 2084 year: 2011 end-page: 2088 ident: bib0018 article-title: Intrawound application of vancomycin for prophylaxis in instrumented thoracolumbar fusions: efficacy, drug levels, and patient outcomes publication-title: Spine – volume: 33 start-page: 160 year: 2012 end-page: 166 ident: bib0019 article-title: Prior vancomycin use is a risk factor for reduced vancomycin susceptibility in methicillin-susceptible but not methicillin-resistant Staphylococcus aureus bacteremia publication-title: Infect Control Hosp Epidemiol – volume: 39 start-page: 6 year: 2016 end-page: 20 ident: bib0013 article-title: Modern methods for vancomycin determination in biological fluids by methods based on high-performance liquid chromatography-A review publication-title: J Sep Sci – volume: 23 start-page: 765 year: 2003 end-page: 770 ident: bib0005 article-title: Topical vancomycin applied on closure of the sternotomy wound does not prevent high levels of systemic vancomycin publication-title: Eur J Cardiothorac Surg – volume: 114 start-page: 1555 year: 2022 end-page: 1561 ident: bib0011 article-title: Topical vancomycin and risk of sternal wound infections: a double-blind randomized controlled trial publication-title: Ann Thorac Surg – volume: 5 start-page: 015 year: 2019 end-page: 018 ident: bib0010 article-title: Topical vancomycin in cardiac surgery to reduce sternal wound infections: a randomized controlled trial at a tertiary cardiac care facility publication-title: J Surg Surgical Res – volume: 20 start-page: 2068 year: 2023 end-page: 2074 ident: bib0012 article-title: A meta-analysis examined the effect of topical vancomycin application in decreasing sternal wound infections post cardiac surgery publication-title: Int Wound J – volume: 12 start-page: 16 year: 2006 end-page: 23 ident: bib0020 article-title: The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus publication-title: Clin Microbiol Infect – volume: 32 start-page: 924 year: 2017 end-page: 928 ident: bib0001 article-title: Serum and wound vancomycin levels after intrawound administration in primary total joint arthroplasty publication-title: J Arthroplasty – volume: 30 start-page: 83 year: 2019 end-page: 86 ident: bib0007 article-title: Role of topical vancomycin reduction of sternal wound infection in patients undergoing cardiac surgery publication-title: Med Forum Monthly – volume: 162 start-page: 143 year: 2021 end-page: 151 ident: bib0015 article-title: The impact of acute kidney injury by serum creatinine or urine output criteria on major adverse kidney events in cardiac surgery patients publication-title: J Thorac Cardiovasc Surg – volume: 114 start-page: 511 year: 2022 end-page: 518 ident: bib0006 article-title: Topical vancomycin reduces the incidence of deep sternal wound complications after sternotomy publication-title: Ann Thorac Surg – volume: 103 start-page: 497 year: 2017 end-page: 503 ident: bib0016 article-title: Vancomycin paste does not reduce the incidence of deep sternal wound infection after cardiac operations publication-title: Ann Thorac Surg – volume: 39 start-page: 1683 year: 2014 end-page: 1687 ident: bib0004 article-title: Safety of topical vancomycin for pediatric spinal deformity: non-toxic serum levels with supratherapeutic drain levels publication-title: Spine – volume: 161 start-page: 1346 year: 2021 end-page: 1355 ident: bib0014 article-title: Stage 1 acute kidney injury is independently associated with infection following cardiac surgery publication-title: J – volume: 26 start-page: 461 year: 2011 end-page: 465 ident: bib0008 article-title: The effect of topical vancomycin applied to sternotomy incisions on postoperative serum vancomycin levels publication-title: J Card Surg – volume: 148 start-page: 1035 year: 2014 end-page: 1038 ident: bib0009 article-title: Topical vancomycin in combination with perioperative antibiotics and tight glycemic control helps to eliminate sternal wound infections publication-title: J Thorac Cardiovasc Surg – volume: 152 start-page: 962 year: 2016 end-page: 972 ident: bib0003 article-title: Prevention and management of sternal wound infections publication-title: J Thorac Cardiovasc Surg – volume: 174 start-page: 1102 year: 2023 end-page: 1112 ident: bib0002 article-title: Topical vancomycin for sternal wound infection prophylaxis. A systematic review and updated meta-analysis of over 40,000 cardiac surgery patients publication-title: Surgery – volume: 98 start-page: 618 year: 1989 end-page: 622 ident: bib0017 article-title: Reduction of sternal infection by application of topical vancomycin publication-title: J Thorac Cardiovasc Surg – volume: 152 start-page: 962 year: 2016 ident: 10.1016/j.clinthera.2024.11.024_bib0003 article-title: Prevention and management of sternal wound infections publication-title: J Thorac Cardiovasc Surg doi: 10.1016/j.jtcvs.2016.01.060 – volume: 33 start-page: 160 year: 2012 ident: 10.1016/j.clinthera.2024.11.024_bib0019 article-title: Prior vancomycin use is a risk factor for reduced vancomycin susceptibility in methicillin-susceptible but not methicillin-resistant Staphylococcus aureus bacteremia publication-title: Infect Control Hosp Epidemiol doi: 10.1086/663708 – volume: 148 start-page: 1035 year: 2014 ident: 10.1016/j.clinthera.2024.11.024_bib0009 article-title: Topical vancomycin in combination with perioperative antibiotics and tight glycemic control helps to eliminate sternal wound infections publication-title: J Thorac Cardiovasc Surg doi: 10.1016/j.jtcvs.2014.06.045 – volume: 103 start-page: 497 year: 2017 ident: 10.1016/j.clinthera.2024.11.024_bib0016 article-title: Vancomycin paste does not reduce the incidence of deep sternal wound infection after cardiac operations publication-title: Ann Thorac Surg doi: 10.1016/j.athoracsur.2016.10.020 – volume: 30 start-page: 83 year: 2019 ident: 10.1016/j.clinthera.2024.11.024_bib0007 article-title: Role of topical vancomycin reduction of sternal wound infection in patients undergoing cardiac surgery publication-title: Med Forum Monthly – volume: 5 start-page: 015 year: 2019 ident: 10.1016/j.clinthera.2024.11.024_bib0010 article-title: Topical vancomycin in cardiac surgery to reduce sternal wound infections: a randomized controlled trial at a tertiary cardiac care facility publication-title: J Surg Surgical Res – volume: 161 start-page: 1346 year: 2021 ident: 10.1016/j.clinthera.2024.11.024_bib0014 article-title: Stage 1 acute kidney injury is independently associated with infection following cardiac surgery publication-title: J Thorac Cardiovasc Surg doi: 10.1016/j.jtcvs.2019.11.004 – volume: 39 start-page: 1683 year: 2014 ident: 10.1016/j.clinthera.2024.11.024_bib0004 article-title: Safety of topical vancomycin for pediatric spinal deformity: non-toxic serum levels with supratherapeutic drain levels publication-title: Spine doi: 10.1097/BRS.0000000000000465 – volume: 20 start-page: 2068 year: 2023 ident: 10.1016/j.clinthera.2024.11.024_bib0012 article-title: A meta-analysis examined the effect of topical vancomycin application in decreasing sternal wound infections post cardiac surgery publication-title: Int Wound J doi: 10.1111/iwj.14074 – volume: 162 start-page: 143 year: 2021 ident: 10.1016/j.clinthera.2024.11.024_bib0015 article-title: The impact of acute kidney injury by serum creatinine or urine output criteria on major adverse kidney events in cardiac surgery patients publication-title: J Thorac Cardiovasc Surg doi: 10.1016/j.jtcvs.2019.11.137 – volume: 36 start-page: 2084 year: 2011 ident: 10.1016/j.clinthera.2024.11.024_bib0018 article-title: Intrawound application of vancomycin for prophylaxis in instrumented thoracolumbar fusions: efficacy, drug levels, and patient outcomes publication-title: Spine doi: 10.1097/BRS.0b013e3181ff2cb1 – volume: 98 start-page: 618 year: 1989 ident: 10.1016/j.clinthera.2024.11.024_bib0017 article-title: Reduction of sternal infection by application of topical vancomycin publication-title: J Thorac Cardiovasc Surg doi: 10.1016/S0022-5223(19)34366-1 – volume: 114 start-page: 1555 year: 2022 ident: 10.1016/j.clinthera.2024.11.024_bib0011 article-title: Topical vancomycin and risk of sternal wound infections: a double-blind randomized controlled trial publication-title: Ann Thorac Surg doi: 10.1016/j.athoracsur.2021.11.012 – volume: 39 start-page: 6 year: 2016 ident: 10.1016/j.clinthera.2024.11.024_bib0013 article-title: Modern methods for vancomycin determination in biological fluids by methods based on high-performance liquid chromatography-A review publication-title: J Sep Sci doi: 10.1002/jssc.201500600 – volume: 26 start-page: 461 year: 2011 ident: 10.1016/j.clinthera.2024.11.024_bib0008 article-title: The effect of topical vancomycin applied to sternotomy incisions on postoperative serum vancomycin levels publication-title: J Card Surg doi: 10.1111/j.1540-8191.2011.01300.x – volume: 32 start-page: 924 year: 2017 ident: 10.1016/j.clinthera.2024.11.024_bib0001 article-title: Serum and wound vancomycin levels after intrawound administration in primary total joint arthroplasty publication-title: J Arthroplasty doi: 10.1016/j.arth.2015.10.015 – volume: 174 start-page: 1102 year: 2023 ident: 10.1016/j.clinthera.2024.11.024_bib0002 article-title: Topical vancomycin for sternal wound infection prophylaxis. A systematic review and updated meta-analysis of over 40,000 cardiac surgery patients publication-title: Surgery doi: 10.1016/j.surg.2023.05.031 – volume: 23 start-page: 765 year: 2003 ident: 10.1016/j.clinthera.2024.11.024_bib0005 article-title: Topical vancomycin applied on closure of the sternotomy wound does not prevent high levels of systemic vancomycin publication-title: Eur J Cardiothorac Surg doi: 10.1016/S1010-7940(03)00033-2 – volume: 12 start-page: 16 issue: Suppl 1 year: 2006 ident: 10.1016/j.clinthera.2024.11.024_bib0020 article-title: The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus publication-title: Clin Microbiol Infect doi: 10.1111/j.1469-0691.2006.01344.x – volume: 114 start-page: 511 year: 2022 ident: 10.1016/j.clinthera.2024.11.024_bib0006 article-title: Topical vancomycin reduces the incidence of deep sternal wound complications after sternotomy publication-title: Ann Thorac Surg doi: 10.1016/j.athoracsur.2021.09.036 |
SSID | ssj0003952 |
Score | 2.4452553 |
Snippet | •Body size and renal status affect plasma exposure after topical sternal vancomycin.•Minimal systemic exposure, even with small body size or impaired renal... Highlights•Body size and renal status affect plasma exposure after topical sternal vancomycin. •Minimal systemic exposure, even with small body size or... Intraoperative topical vancomycin has been widely used in several surgical fields to prevent wound infection. However, there have been limited studies on the... Purpose Intraoperative topical vancomycin has been widely used in several surgical fields to prevent wound infection. However, there have been limited studies... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 135 |
SubjectTerms | Administration, Topical Adults Aged Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - blood Anti-Bacterial Agents - pharmacokinetics Antibiotics Body Size Body Surface Area Cardiac surgery Cardiac Surgical Procedures - methods Cardiovascular disease Chronic illnesses Coronary vessels Creatinine Diabetes End-stage renal disease Enzymes Female Glomerular Filtration Rate Heart surgery Hemodialysis Humans Infections Internal Medicine Kidney diseases Kidney Failure, Chronic - complications Kidney Failure, Chronic - physiopathology Male Middle Aged Patients Pharmacokinetics Plasma Postoperative period Renal function Sternum Sternum - surgery Surgery Surgical Wound Infection - prevention & control Systemic exposure Topical vancomycin Vancomycin Vancomycin - administration & dosage Vancomycin - blood Vancomycin - pharmacokinetics Variables Wound infection |
SummonAdditionalLinks | – databaseName: Elsevier SD Freedom Collection dbid: .~1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fi9QwEA7HPYgvouev6ikjyD1db9s06bb3pusuh3C6uHtybyFNUlnBdrF74Prgi_-4M03b5dBDwZcW2gkJ-SYzX5uZCWMvtUulEM6GSAVsKBIrwzzDC1IHnmljXGkpG_n8XXp2Id5eyss9NulzYSissrP93qa31rp7Mupmc7RerUYUloS-HfmxoCIqnOywEGPS8pMfuzCPJG9P3SHhkKSvxXhR9mGb54QfilycUDlPLm7yUDcx0NYTze6yOx2FhFd-lPfYnqsO2K3zbpP8gB3NfTnq7TEsd9lVzTEcwXxXqHp7n_1c1mvCCD4i9PWXLTaHuUbY4T0qOOCQYeFrRMPUfnLwpk1phEmrVAYWPqP6FHwF5AbqEj44kp6hsyTAQVcWXtd2C4vVdwf4wBdIXxmYflvX9HPyAbuYTZeTs7A7lCE0yLU2oSudQxZRaiOLXCfWxak0MimllohEaS3Cm-eGxy7SHPGPUYjrJE0jR4mvInnI9qu6co8ZZGkZJfjWxUILY-KiGNOOMpKUoqDDDgMW9UCota-9ofqgtM9qwE4Rdvglo_AWsKwHTPWppWgMFfqHvzcd_6mpa7pF3ahYNVxF6jfFC9jp0PKa7v5bt4e9XqmhpwRZMjI7tI8BezG8xoVPuzm6cvUVyYgxlVqSWcAeeX0cZglJJrKQlD_5n5E9Zbc5HXbchqgfsv3N1yv3DBnYpnjeLrFf3Ukvuw priority: 102 providerName: Elsevier |
Title | Topical Vancomycin Paste Over the Sternal Edge During Cardiac Surgery: Effects of Renal Function and Body Size on Systemic Exposure |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0149291824003722 https://www.clinicalkey.es/playcontent/1-s2.0-S0149291824003722 https://dx.doi.org/10.1016/j.clinthera.2024.11.024 https://www.ncbi.nlm.nih.gov/pubmed/39706762 https://www.proquest.com/docview/3163431531 https://www.proquest.com/docview/3147973258 |
Volume | 47 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELfYJiFeEIyPBUZ1SGhPy0gc52svaButCmilWjvUN8uxHTQkkkI6ifLAC_84d_mqkBjw0kiN3UT9nX0_23e_Y-yFslEohDUuUgHjisCEbprgB1IHniitbW4oG_l8Eo0vxdtFuGg33Ko2rLKbE-uJ2pSa9shfBkgc0NmhybxafnGpahSdrrYlNLbYDkmXUUhXvOgXXF6Q1hV3aBXg8tRPfovvoszDOscJF4lcHJGUJxc3eaeb2GfthUb32N2WPsJJg_d9dssWu-z2eXtAvssOpo0U9foQ5pvMquoQDmC6EaleP2A_5-WS8IEPCHv5eY3dYaoQcniPxg34yjBr9KFhaD5aeF2nM8JZbVAaZk029TE06scVlDlcWGo9QkdJYIMqDJyWZg2zq-8W8ItGHP1Kw_DbsqSNyYfscjScn43dtiCDq5FnrVybW4sMIlc6zFIVGOtHoQ6DPFRhwkVuDEKbppr71lMcsfexEVdBFHmWkl5F8IhtF2Vh9xgkUe4FeNf6Qgmt_SyL6TQZCUqWUaFDh3kdEHLZ6G7ILiDtk-yxk4QdrmIkXhyWdIDJLq0UJ0KJvuHfXeM_dbVVO6Ar6cuKS6-OhUvJlCj0Nog5d9hx37PlLA0X-b_H7nd2JfsnbQzdYc_72zjo6SRHFba8pjYiJpmlMHHY48Ye-38JCSYykIg_-fuPP2V3OJUyrgPQ99n26uu1fYb8apUN2NbRD39QD6UB2zl58248wevpcDK9-AVWYyji |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VVAIuCMorUGCQoKe6xOu1Y1dCiLaJUtqEqE1Rb8vau0ZFIg44FYQr_4ffyIxfERIFLr0kUrzrR-bbmW-88wB4pm3gS2mNQ1TAONIzvhOF9EHUQYQ6SWxqOBt5OAoGJ_LNqX-6Aj_rXBgOq6x1YqGoTZbwO_IXHhEHMnYEmVezzw53jeLd1bqFRgmLA7v4Si5b_nJ_j-T7XIh-b7I7cKquAk5CZGHu2NRaMoOpTvw40p6xbuAnvpf62g-FTI2h-4uiRLi2owU9gEuDhPaCoGM5c1N6dN4rsCo9cmVasLrTG42PGt3vRUWPH_Y7HBG54W8RZZzrWGRVkVsq5BYXDxXyInt4Ed8t7F7_JtyoCCu-LhF2C1bsdA2uDqst-TXYGJfFrxebOFnmcuWbuIHjZVnsxW34MclmjAh8R0DLPi1oOo41gQzf0nJCumU8LitSY898sLhXJFDibgHhBI_L_O1tLOst55ileGR5dJ9MM8ML9dTgTmYWeHz23SL9UJZjP0uw922W8avQO3ByKcK6C61pNrX3AcMg7Xh01LpSyyRx47jL-9dEieKYWyu2oVMLQs3KSh-qDoH7qBrZKZYd-U2KvtoQ1gJTdSIrqV5F1ujfU7t_mmrzSoXkylW5UJ0i-i5iKHGwr9cVog3bzcyKJZXs5_8uu17jSjVXWi6tNjxtDpOa4b0jPbXZOY-RXS7s5IdtuFfisfmXiNIS5wnEg7-f_AlcG0yGh-pwf3TwEK4LbqRchL-vQ2v-5dw-InY3jx9XSwrh_WWv4l-vfWPn |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VIlVcEJSXS4FBgp5qaq_Xr0oIQZOopbREJEW5LevddVUk4oBTQbjyr_h1zPgVIVHg0ksixbt-ZL7Z-cY7D8aeKBuFQljjIhUwrghM6KYJfiB14InS2uaGspGPjqP9E_F6Ek5W2M82F4bCKts1sVqoTaHpHflOgMQBjR1CZidvwiKGvcGL2WeXOkjRTmvbTqOGyKFdfEX3rXx-0ENZP-V80B_v7btNhwFXI3GYuza3Fk1irnSYpSow1o9CHQZ5qMKEi9wYvNc01dy3nuL4MD4O4iqIIs9SFqcI8LxX2NU4CH3SsXjSOXtekFbdfsgDcXnqJ7_FllHWY5VfhQ4qF8-ojCgXF1nGi5hvZQEHN9j1hrrCyxprN9mKna6ztaNmc36dbQ3rMtiLbRgvs7rKbdiC4bJA9uIW-zEuZoQNeI-QKz4tcDoMFcIN3qJiAd4yjOra1NA3pxZ6VSol7FVg1jCqM7l3oa68XEKRwztLowdopAlooKYGXhVmAaOz7xbwh7ow-5mG_rdZQS9Fb7OTSxHVHbY6Lab2HoMkyr0Aj1pfKKG1n2Ux7WQjOcoyarLoMK8VhJzVNT9kGwz3UXaykyQ79KAkfjksaQUm25RWXIQl2qV_T43_NNWWzWJSSl-WXHpVHF5KUKKw3yDm3GG73cyGL9U86P8uu9niSnZXWiqZwx53h3HBoV0kNbXFOY0RMZV4ChOH3a3x2P1LSG6R_UR84-8nf8TWUHflm4Pjw_vsGqeOylUc_CZbnX85tw-Q5s2zh5U-Aftw2Qr8CzLCZrc |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Topical+Vancomycin+Paste+Over+the+Sternal+Edge+During+Cardiac+Surgery%3A+Effects+of+Renal+Function+and+Body+Size+on+Systemic+Exposure&rft.jtitle=Clinical+therapeutics&rft.au=Tsai%2C+Meng-Ta%2C+MD%2C+PhD&rft.au=Hu%2C+Yu-Ning%2C+MD&rft.au=Roan%2C+Jun-Neng%2C+MD%2C+PhD&rft.au=Kan%2C+Chung-Dann%2C+MD%2C+PhD&rft.date=2025-02-01&rft.issn=0149-2918&rft.volume=47&rft.issue=2&rft.spage=135&rft.epage=142&rft_id=info:doi/10.1016%2Fj.clinthera.2024.11.024&rft.externalDBID=ECK1-s2.0-S0149291824003722&rft.externalDocID=1_s2_0_S0149291824003722 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01492918%2FS0149291825X00023%2Fcov150h.gif |